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Efficient delivery of anticancer drugs into tumor tissues at maximally effective and 
minimally toxic concentrations is vital for therapeutic success. At present, no method 
exists that can predict the spatial and temporal distribution of drugs into a target tissue 
after administration of a specific dose. This prevents accurate estimation of optimal 
dosage regimens for cancer therapy. Here I present a new method that predicts 
quantitatively the time-dependent spatial distribution of drugs in tumor tissues at sub-
micrometer resolution. This is achieved by modeling the diffusive flow of individual drug 
molecules through the three-dimensional network of blood-vessels that vascularize the 
tumor, and into surrounding tissues, using molecular mechanics techniques. By 
evaluating delivery into tumors supplied by a series of blood-vessel networks with 
varying degrees of complexity, I show that the optimal dose depends critically on the 
precise vascular structure. Finally, I apply my method to calculate the optimal dosage of 
the cancer drug Doxil into a section of a mouse ovarian tumor, and demonstrate the 
enhanced delivery of liposomally administered doxorubicin when compared to free 
doxorubicin. Comparison with experimental data and a multiple-compartment model 
show that the model accurately recapitulates known pharmacokinetics and drug-load 
predictions. In addition, it provides, for the first time, a detailed picture of the spatial 
dependence of drug uptake into tissues surrounding tumor vasculatures. This approach is 
fundamentally different to current continuum models, and reveals that the target tumor 
vascular topology is as important for therapeutic success as the transport properties of the 
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Knowledge of the efficiency of drug delivery from the vasculature into target 
tissues is important for estimating the optimal dosage regimen for a given drug1. This is 
particularly significant for anticancer drugs, which typically have narrow therapeutic 
windows2,3. 
Drug dosing for humans is often derived from animal studies, which are refined in 
human clinical trials4. Adaptation to individual patients is achieved by scaling the 
standard dose based on weight or body surface area (BSA) using empirical calculations, 
with the DuBois and Mosteller formulas being the most commonly used5. BSA based 
regimens have been criticized, as they cannot account for the 4 to 10-fold variation in 
drug clearance typically observed within any particular patient pool6. In cancer patients 
calculations based on these methodologies have resulted in both increased toxicity due to 
overdosing7 as well as decreased efficacy and possible development of drug-resistance 
due to underdosing during chemotherapy8. This highlights the need for better tools to 
predict doses that fall within the therapeutic window9. 
 Systemic delivery of therapeutics into tissues relies upon the vascular network, 
which also delivers oxygen and nutrients. In healthy human tissues (e.g. liver, kidney, 
muscle), cells are typically located ~50 µm from a blood vessel10, which results in good 
tissue distribution of pharmaceuticals with high permeability. In contrast, drug delivery 
into tumor tissue is complicated by the leaky and defective tumor vasculature. The 
growth of the neovasculature recruited to supply tumor cells is typically slower than the 
proliferation rate of cells inside a tumor11,12. This results in a significant increase in the 
average normal distance to the nearest vessel for cancer cells (>100 µm) and a lower 
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overall density of blood vessels inside a tumor13,14. Together with reduced lymphatic 
drainage, this creates an acidic and hypoxic extracellular environment for tumor cells at 
larger distances from the vasculature due to accumulation of byproducts of cell 
metabolism (e.g. lactic acid and carbonic acid) and oxygen starvation15. Targeting cells in 
these deeply buried microenvironments with chemotherapy is challenging, because drugs 
may not diffuse efficiently enough through the interstitial space to reach them16, and the 
drugs that do reach deep into these tissues may be less active due to the acidic 
microenvironment17.  
 The ability of anticancer therapeutics to come into contact with all proliferating 
cells within a non-operable tumor is vital for prolonging remission or preventing relapse. 
To improve delivery into solid tumors nanoparticle-based cancer drugs have been 
developed that exploit the enhanced permeability and retention (EPR) effect18 by 
penetrating the leaky junctions of the tumor vasculature and accumulating inside tumor 
tissues19.  
 Simple drug delivery models typically divide the organism into a number of 
compartments such as blood vessel, peripheral tissue, and tumor tissue. How much of a 
given compound was delivered to the tumor is calculated by assigning first order rate 
constants to model the transport between the various compartments and by taking into 
account clearance20,21. While these models can be parameterized to capture uptake in the 
tumor microenvironment implicitly, the spatial resolution of the drug in the target tissue 




Models that incorporate the spatial distribution of a drug have applied continuum 
finite-element22 and finite-difference methods16, fluid-mechanics formalisms23,24, and 
time evolution of differential equations21,25,26. These models generally treat both the 
blood vessels and the tissue as a homogeneous continuum. While this approach works 
well for simple systems, solving the boundary conditions of realistic vascular structures, 
which are typically highly complex, is computationally prohibitive. Thus, no model 
currently exits that can capture the complexity of the physiological micro-environment of 
tumors, such as the structure of the blood vessels, and the preferential uptake of drugs 
and nutrients by particular regions within the tumor.  
Here, I present a new method that predicts the spatial drug delivery efficiency into 
a target tissue. To achieve this, I simulate the diffusive transport of compounds through a 
vasculature towards target tissues using molecular mechanics methods in complex 
geometrical volumes. The model works for both molecular solutes as well as 
nanoparticle-based delivery systems that carry thousands of individual pharmaceutically 
active compounds.  
 
Methods 
Modeling the vasculature, endothelium, and surrounding tissues 
Stochastic drug transport towards target tissues is modeled by pseudo-random 
diffusion through a micrometer-resolution three-dimensional (3D) model of vasculature 
and surrounding tissue (see Figure 1). Corrosion casts and micro-computed tomography 
(µCT) scans of tumor vasculatures show branched networks of arteries, capillaries, and 
veins that are approximately cylindrical in cross section13. In order to capture the vascular 
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network efficiently I modeled veins and arteries as linked cylinders of constant radius, 
with a sphere at either end to allow modeling of bends and branches as well as changes in 
radius (see Figure 1). This greatly facilitates tracking of drug diffusion through the 
various compartments representing the vasculature and surrounding tissues, which makes 
the simulation of a large number of particles tractable with reasonable computational 
effort.  
Tissues surrounding the vasculature are modeled as rectangular prisms that are 
connected in three-dimensions. This allows calculation of the spatial distribution of drug 
flow and concentration in tissues. For the present study, I have assigned the particle 
diffusivity to be isotropic for the vasculature and tissues. However, different diffusivities 
in x, y, and z can be assigned for each element of the tissue or vasculature (e.g. dependent 
of vessel radius or related to the distance from the closest vessel), and there is no major 
computational overhead associated to adding microscopic structural features, such as 
individual tumor cells or blood lakes, to these tissues. While the tissue mesh allows for 
full spatial and temporal tracking of particle concentrations within tissues, the particles 
themselves are able to move freely in three dimensions and their position is not 






Figure 1 | Drug diffusion model schematic and drug equilibration inside the 
vasculature. A. A three-dimensional tissue model is created by mapping of the 
vasculature and surrounding tissues onto simple geometric shapes (cylinders, spheres, 
and a cubic grid) that allow rapid computational boundary determination. The vasculature 
is modeled as a chain of cylinders, connected via spheres that allow branching as well as 
changing of the direction and radius of blood vessels. Interstitial space and target tissues 
are represented as a cubic grid. Drugs are represented by individual particles that diffuse 
through the system under the influence of Brownian motion, with the diffusion constant 
depending on the location of the drug (i.e. vessel or tissue). Drugs incident on the walls 
of the vasculature are transferred back and forth between the vessel and the tissue with a 
given probability via a kinetic Monte Carlo scheme. The probability, p+
tumor, of drug 
transport from blood vessels into tumor tissues was determined from rate constants 
provided in a multicompartment model. B. Kinetics of drug equilibration within the 
vascular network shown in the inset. The blood vessel components are small arteries 
(red), arterioles (light red), capillaries (pink), venules (light blue), and veins (blue). The 
figure demonstrates rapid equilibration of an injected drug dosage throughout the 
vasculature. C. Two frames show an evolution of a simulation trajectory. Drugs (brown) 
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transfer out of the vessel and disperse into the tissue. As only a small number of particles 
leave the vessel at each simulation step, particle concentrations remains high in vessels. 
 
Drug delivery system 
Here I study both the delivery and transportation of the molecular anticancer drug 
doxorubicin and Doxil, an FDA-approved liposomal formulation of doxorubicin. Doxil 
liposomes are around 100 nm in diameter and PEGylated to reduce uptake by the MPS 
and increase clearance half-time20. The initial distributive pharmacokinetic phase of 
doxorubicin has a half-life of ~5 minutes, whereas the terminal elimination half-life 
ranges between 20-48 minutes27. Conversely, Doxil’s distributive phase is approximately 
5 hours and has an elimination half-life of between 47 and 59 hours.28 The 
pharmacokinetic profile of Doxil suggests that the liposomes are largely confined to the 
vasculature during the distributive and eliminative steady-states, whereas free 
doxorubicin is rapidly absorbed by tissues and leads to a large volume of distribution 
with considerably more side-effects due to indiscriminate tissue uptake20,29. Both 
doxorubicin and Doxil are well-studied chemotherapeutics allowing comparison to 
previous pharmacokinetic models and clinical data. Temporal release of drugs from 
liposomes has been measured in vitro30,31 and described via mathematical models,32 
roughly following an exponential decay of drug released over time.  
 
Drug diffusion in the vasculature and surrounding tissues 
Diffusion of the drugs and the delivery system was modeled by a fixed step-size 
spherical random walk in combination with a Metropolis Monte Carlo scheme to hop 
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between vasculature and surrounding tissues (summarized in Figure 1). A time-step of Δt 
= 1 second was chosen with a fixed Einstein diffusion length (i.e. step-size) inside the 
vasculature of √(6DΔt) in a spherically random direction.  
For the vasculature a diffusion coefficient of Dvasc = 1.0x10
-7 cm2/s was chosen for Doxil, 
which corresponds to the theoretical random diffusion of a spherical liposome of 100 nm 
diameter through capillary blood. For the small molecule drug doxorubicin Dvasc = 
1.0x10-5 cm2/s was chosen, which is the same order of magnitude as other molecules of 
similar size. Regarding the surrounding tissues, diffusivity measurements in vivo are 
challenging at present. The diffusion length of doxorubicin inside the interstitial space of 
tumor tissues was chosen to be Dtiss = 1.0x10
-9 cm2/s. This value is consistent with a drug 
that delivers well in tissues with dense vasculature. The diffusive lengths of nanoparticles 
are certainly much lower. The diffusivity of Doxil liposomes was based on measurement 
of a nanoparticle of similar size and mass in a collagen matrix. Many nanoparticles 
diffuse on the order of 10-13 cm2/s in tissues , but the selection of Dtiss = 1.0x10
-12 cm2/s is 
closer line with previous simulations of Doxil, and yields a similar drug penetration in the 
tumor, due to the square root dependence on diffusivity on permeation length.  
For the present study, I model only diffusive flow of liposomes through the 
vasculature, across the endothelium, and into and across surrounding tissue. Time-
dependent blood flow and viscosity, as well as more fine-grained tissue structures can be 
implemented straightforwardly to refine this model. I show below that equilibration 
inside the vasculature is much faster than trans-endothelial transport and diffusion in 
surrounding tissues. Thus, flow was ignored for the present study. Further confidence in 





Tumor endothelium has leaky junctions between cells, resulting in increased 
transport of large complexes including liposomes up to around 500 nm in diameter33–35. 
This can be modeled by adjusting the permeability for individual segments of the 
vasculature. Since I are simulating the delivery of individual molecules rather than using 
a continuum representation, the first-order rate constant for transport between 
compartments must be converted into a per-particle transport probability. 
This is achieved using a kinetic Monte Carlo approach. In brief, the experimentally 
determined first-order rate constant of a drug exiting a compartment (e.g. Doxil moving 
from blood into tumor tissue) was converted to a corresponding Monte Carlo probability 
for this process. The probability of trans-endothelial transport was determined from 
fitting to pharmacokinetic data for Doxil (Figure 3A). This probability, ptrans, is obtained 
by equating the number of molecules or nanoparticles N(t) in a vessel at some time t = 
n·Δt (n = 0,1,2,…) calculated by transforming a first-order pharmacokinetic rate equation:  
𝑁(𝑛∆𝑡) = 𝑁0𝑒
−𝑘∙𝑛∆𝑡        (Eq. 1) 
into a Monte Carlo population decay equation: 
𝑁(𝑛∆𝑡) = 𝑁0(1 − 𝑝𝑡𝑟𝑎𝑛𝑠)
𝑛∆𝑡                      (Eq. 2) 
Here N0 is the initial population, k is the first-order rate constant, n is the number of 
simulation steps, and Δt is the time-step passed in the simulation, and ptrans is the Monte 
Carlo probability of a change of state (i.e. transport event or clearance event). The 
solution of this equation gives the rate-derived transport probability: 
𝑝𝑡𝑟𝑎𝑛𝑠 = 1 − 𝑒
−𝑘∆𝑡                   (Eq. 3) 
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Converting the rate constant into a Monte Carlo probability in this approach is 
compatible with existing pharmacokinetic compartment models (Figure 3A).  
It is important to note that pharmacokinetic compartment models, which follow 
Eq. 1, contain no information on particle proximity to the vessel walls and hence assume 
that all particles can potentially exit the compartment at each simulation step. While this 
works well for clearance, it is a poor approximation for transport across the endothelium 
(Figure 3B).  
In a structural model, such as the one presented here, the final location of a 
molecule in the system depends on the precise trajectory through the vasculature and 
surrounding tissues. Only molecules within a volume element surrounding the vascular 
surface may traverse the endothelium. For each cylindrical vascular segment this volume 
element is: ΔV = c·vav·Δt, where vav is the mean speed of the drug in the blood vessel, 
and c is a constant that depends on the geometry of the vessel segment. This limits the 
fraction of drugs which can possibly leave each vessel within the next simulation step 
(Figure 3C). The sum of all volume elements of the vasculature scales non-trivially with 
the total volume of the entire compartment (i.e. the blood vessel). This leads to improper 
scaling of the rate-derived probability (Eq. 1), which would ultimately need to be scaled 
in each vascular segment to perfectly match a compartmental model. For fixed transport 
probabilities (e.g. ptumor, pclearance, ptissue, pdelivery), the final delivered dose scales linearly 
with the surface area to volume ratio (Figure 3F), i.e. delivery depends on the three-
dimensional structure of the vasculature. Figure 3 demonstrates that incorporating surface 




At present, my model makes no assumptions about the mechanisms of trans-
endothelial transport. However, mechanistic and physiological details such as increased 
permeation within predefined leaky endothelial regions or vessel sub-sections can be 
implemented without loss of efficiency. Furthermore, anisotropic diffusivities in different 
vessel segments, drag forces, and other biases can be straightforwardly incorporated. 
 
Drug injection, clearance, and delivery 
Injection is simulated by placing all drug molecules at a point source in the artery 
and equilibrating to uniform concentration throughout the vasculature, before enabling 
trans-endothelial transport and clearance. Clearance by macrophages, liver, and kidneys 
is simulated as a random removal using a kinetic Monte Carlo scheme with rate kclearance.  
Delivery from the large vessels (arteries or veins) into surrounding tissues is 
modeled using a kinetic Monte Carlo approach outlined above (Eq. 2) with a rate 
constant of kdelivery = (kclearance / 100). This value is based on the observation of a much 
slower clearance (plasma half-life t½ > 180 hrs) of fluorescently loaded nanoparticles and 
free drug within mouse tissues when compared to the normalized plasma bound 
concentration of nanoparticles and free drugs36–39. Delivery and accumulation are 
visualized by recording the total number of liposomes in target areas and tissue cross 
sections, as well as plotting their time evolution, peak and average concentrations, and 




Figure 2 | Simulated drug delivery into model tissues of different complexity. Each 
panel in the first column shows a heat map of the final drug concentrations at the end of a 
simulation with shared parameters. Each vasculature is embedded in a tissue grid of 
300x300x300 voxels with a linear dimension of 1 mm, resulting in a voxel volume of 
37.0 µm3. The second column shows the final drug concentration through two different 
linear cross sections of the tissue (red & blue indicated in the first column), while the 
third column shows the time-dependent drug concentration at two target sites within the 
tissue (green & purple indicated in the first column). After injection of 106 drug particles 
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into a source artery, each system was equilibrated by allowing particles to diffuse freely 
throughout the vasculature without allowing their exit into surrounding tissue. The 
therapeutic window of the drug is indicated for the cross-sectional profiles (red = toxic, 
blue = ineffective). A. Drug delivery into a simple vasculature model composed of 
parallel capillaries with 50 µm, and 100 µm spacing, representing healthy and tumor 
tissue averages, respectively. The concentration cross-section shows that narrow capillary 
spacing (i.e. healthy tissues) result in good drug delivery with all sections falling into the 
therapeutic window, while increasing the capillary distance results in therapeutic gaps 
between the capillaries. The pharmacokinetics at target sites in the middle of two 
capillaries shows an up to 50% smaller area under the curve for tumor tissues as well as a 
lag in reaching peak concentration. B. Drug delivery into a simple branched micro-tumor 
model with uneven capillary spacing. While the average capillary spacing is very similar 
to the parallel tumor tissue in panel A, the two-dimensional nature of the capillary 
network results in much larger regions that are outside the therapeutic window in the 
cross-sectional analysis. A target site with a close proximity to a variety of vessels shows 
very high drug loads, whereas a site embedded near the center of large loops receives a 
five times lower dose. C. A more complex branched and looped planar capillary web 
model, shows similar behavior than the branched model in panel B. This figure highlights 
that vessel geometry greatly influences drug delivery efficiency. Choosing a target site 
that is located further away from the capillaries in an acute angle (purple) shows better 
drug delivery, despite a time-lag for drugs arriving at the site, compared to a site situated 





Equilibration in the vasculature 
A human red blood cell takes less than one minute to circulate through the body40. 
For a small molecule or delivery vehicle suspended in blood, this means that equilibration 
inside the vasculature is orders of magnitude faster than diffusion across vessel walls. 
Since my model does not currently include blood flow, solute molecules and 
nanoparticles are first equilibrated inside the vasculature. This prevents biasing the 
simulation results with respect to the injection site. Figure 1B shows that random 
diffusion alone is sufficient to equilibrate the concentration in the vasculature within 
10,000 ms. I found that all vasculatures tested here efficiently equilibrated within 10 
minutes CPU time for an injection of 1 million liposomes. This corresponds to 5x10-9 of a 
typical dose of 100 mg of Doxil within a simulation volume of a 1 mm3 microtumor, 
corresponding to ~1x10-8 the volume of an average human body.  
 
How vascular structure impacts tissue penetration  
Figure 2 shows diffusion of doxorubicin through three vascular structures of 
different complexity. To simplify visualization, analysis, and model validation, all 
vasculatures in the present study are constructed in a plane. However, all vasculatures 
exist as full three-dimensional objects and my model and software implementation does 
not require them to be confined to a plane.  
Tissue cross-sections (second column of Figure 2) show that, as expected, the 
maximum drug concentration declines steeply with distance from the nearest capillary. 
The overall distribution of drugs throughout the tumor tissues depends directly on the 
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localized spacing of capillaries. As expected, delivery into tissue regions that are far 
removed from blood vessels is poor, while delivery into well-vascularized tissues is high. 
For example, for parallel capillaries increasing the spacing from 50 µm13,14,41, which 
corresponds to the mean spacing of healthy tissues to 100 µm13,14,42,43, which is a low 
mean spacing for tumors, reduces the total delivered dose by a factor of 6 (Figure 2A). 
The third column in Figure 2 shows the time-evolution of the drug concentration 
within two target regions over the course of the delivery simulation. Numerical 
integration provides the pharmacokinetic area under the curve for each target area. These 
plots show that the time-evolution of the concentration, peak concentration, area under 
the curve, and rates of change vary with the distance of the target area relative to the 
vasculature. 
Cross-sections of more complex branched vasculatures reveal a similar general 
trend (Figure 2BC), but show that the average spacing of capillaries is a poor predictor of 
drug delivery. Instead, the distance-weighted vascular volume surrounding a target tissue 
is the key indicator of delivery efficiency. Indeed, drug concentrations are particularly 
high at the branching points of capillaries. In the proximity of small branching angles 
(<30°) concentrations are approximately triple compared to similar distances of straight 
capillaries, and are still 15% larger at 90° branches. This is due to a higher vessel surface 








Grouping the key structural features of the spatial tumor model into individual 
compartments (i.e. vasculature, tumor tissue, peripheral tissues, and clearance) allows 
direct comparison of my model with both experimental pharmacokinetic measurements 
as well as previous kinetic models. Figure 3A shows clinical measurements of the blood 
concentration of Doxil at various times after injection29. The data show that Doxil is not 
cleared rapidly, reflecting the long clearance half-time. Figure 3A shows that these data 
can be used to calibrate clearance parameters for a simple four-compartment model 
(blood, tumor, peripheral tissue, and clearance), developed by Wong et al.20 as well as the 
equivalent clearance kinetics predicted by my new structural model.  
Drug clearance data is typically available from clinical studies that measure the 
mean blood concentration of drugs in patients as a function of injection dosage8,29. 
However, plasma concentrations can differ by over one order of magnitude within hours 
of monitoring between individual patients6. In the present study, I fitted the drug 
concentration in blood to clinical clearance data from patients that were injected with 25 
or 50 mg/m2 of Doxil29, respectively to obtain the clearance rate, in agreement with 
previous studies20. 
Unfortunately, the clinical clearance rate does not allow estimating the rate of 
uptake for tumor and peripheral tissue. To estimate the total amount of drug accumulated 
in the tumor Wong et al. explored a range of different rate constants for peripheral tissue 
and tumor uptake (k+
tissue, k+
tumor) and efflux (k–
tumor, k–
tissue)20. Figure 3B shows that in the 
absence of a three-dimensional vasculature (i.e. using the stochastic Monte Carlo 
approach to move drugs between structure-less compartments) the time dependent 
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accumulation of drugs in tumor predicted from the four-compartment model can be 
replicated quantitatively. The variation of the EPR effect (i.e. varying the ratio of k+
tumor 
to k–
tumor) can also be replicated if diffusion of all drugs into the tumor is considered in 
the absence of structural information (Figure 3C).  
However, for a three-dimensional vasculature and tumor tissue model the 
functional form of Doxil accumulation, as well as the amount in the tumor tissue is 
different from the compartment model (Figure 3D). This is due to an oversimplification 
of the compartment model, which moves any particle with the same probability to a new 
compartment, irrespective of its location in the vasculature or tissue. This ignores the fact 
that the probability to cross into the surrounding tissues is dependent on location and flow 
dynamics. This effect is particularly prominent for vessels with larger diameters, as the 
transport probability for a structural model scales approximately with the surface area of 
the vessel (i.e. the number of particles near the vessel walls), while compartment models 
scale with vessel volume (i.e. the total number of particles).  
The uptake kinetics and total amounts delivered differ significantly between 
structural and structure-less models (c.f. Figure 3BD). Remarkably, comparison of the 
time-dependent uptake kinetics of Doxil in all three vasculatures shown in Figure 2 was 
found to be similar in functional form (Figure 3E), yet the ultimate dose delivered is 
different for all vasculatures. This shows that pharmacokinetics alone are poor indicators 
of effective drug doses at target sites and cannot provide information on how evenly 
drugs are distributed within a tumor. The total amount of drug delivered into the tumor 
scales approximately with the surface to volume ratio of the vascular network embedded 
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into the tissue (Figure 3F), highlighting the importance of vascular structure for drug 
delivery. 
 
Figure 3 | Compartment-based pharmacokinetics of Doxil delivery into tumors. A. 
Comparison of the time dependence amount of Doxil in blood (i.e. the total vasculature) 
after injections of 50 mg/m2 from clinical data (Gabizon et al.), a multi-compartment 
model (Wong et al.), a spatial compartment model: ‘structure off’ (i.e. drugs were moved 
in and out of the 3D vasculature without regards to their physical position), and the 
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spatial model presented in this study: ‘structure on’. All three models are able to 
reproduce the clinical data. B. Time dependent uptake of Doxil in the tumor for different 
ratios of k+
tumor:kelimination, which quantify the strength of the EPR effect. The functional 
form of the drug uptake modeled by the compartment model proposed by Wong at al., 
(dashed line) can be reproduced for a 3D blood vessel compartment if all drugs leave the 
vessel with identical probability (“structure off”, shown as a solid line). However, when 
only drugs incident on the vessel wall may cross into surrounding tissues, the shape of the 
curve changes and the number of drugs reaching the tumor decreases by an order of 
magnitude. C. In the compartment model, and when the position of the drug in the 
vasculature is not taken into account, the concentration of Doxil over time depends on the 
ratio of the transport into (k+
tumor) and out of (k-
tumor) the tumor for a given ratio of 
k+
tumor:kelimination. D: When the position of the drug inside the vasculature is taken into 
account the dependence of drug delivery into tissues on the back-transport rate (k-
tumor) is 
almost negligible. The overall functional shape is different from the compartment model 
(panel C), and the total drug uptake is an order of magnitude smaller. This difference 
arises from the volumetric modeling of the vessel, which restricts transport across the 
endothelium to drugs that are within the volume element ΔV = c·vav·Δt, where vav is the 
mean speed of the drug in the blood vessel, and c is a constant that depends on the 
geometry of the vessel segment. This result implies that the structure cannot be ignored 
and that extravasation is more likely than intravasation, since the solid angle of a 
capillary is small compared to the surrounding tissues for a drug near a vessel. E: 
Comparison of the time-dependent uptake of Doxil in the three vasculatures shown in 
Figure 2, with identical simulation parameters. The absolute dose delivered into the 
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tumor varies between the three systems. F: The surface to volume ratio of the all 
vasculatures scales linearly with the delivered peak concentration for the vascular 
structures in Figure 2. The least-squares linear regression trend-line suggests that [C], the 
amount of therapeutic delivered to the tumor, is roughly scales with x, the surface-to-
volume ratio of the vascular network embedded into the tissue. This shows the 
importance of vascular structure in delivery when providing uniform kinematic variables 
(i.e. tissue diffusivity and trans-endothelial probabilities) in the context of different 
vascular systems.  
 
Transendothelial transport and tissue diffusivity 
As outlined in Figure 3, drug delivery into a tumor depends strongly on clearance 
kinetics from blood, diffusivity within the tumor tissues, and transendothelial 
permeability. Accurate spatial mapping of drug delivery into tumor tissues requires 
realistic parameters for these quantities. Figure 4 shows the effect of variation in 
transendothelial permeability and tissue diffusivity for a fixed clearance rate. The figure 
demonstrates graphically that while transendothelial permeability is vital in getting drugs 
into the tumor, tissue diffusivity is the key determinant for efficient delivery into deeply 
buried tissues. 
Comparison of the delivery of Doxil, modeled as spherical particles with 100 nm 
diameter with a tissue diffusivity of 10-12 cm2/s, transendothelial permeation probability 
of 6.33x10-5 s-1, and clearance rate of k = 2.28x10-3 hr-1, with doxorubicin (1.7 nm 
diameter, tissue diffusivity = 10-9 cm2/s, transendothelial permeation permeability = 
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4.36x10-4 s-1, clearance rate of k = 1.57 hr-1) reveals that doxorubicin, due to its small size 




Figure 4 | Three-dimensional final distribution of drugs in tumor tissues as a 
function of the trans-endothelial transport probability and tissue diffusivity of drugs 
in the tumor. A: A heatmap plot shows the number density of drugs inside the 
vasculature and diffused into the tissue at the end of the simulation for different ranges of 
trans-endothelial transport probability and tissue diffusivity. Systematic exploration of 
these two properties allows narrowing down the pharmacological transport features 
required for a drug to be delivered efficiently into a tissue supplied by a given 
vasculature. For the vasculature shown in this figure the optimal range of parameters is 
highlighted by a green box. Outside this parameter range the structure of the vasculature 
effectively prevents delivery of drugs at sufficient concentrations to treat the tumor.  
B: Analysis of the drug distribution across the tumor tissue allows precise spatial 
mapping of the therapeutic efficiency. For each row the total number of drugs released 
into the tissue is approximately constant. However, the diffusive length into the tissue 
varies with an expected square-root-dependence of the diffusion coefficient. Thus, tissue 
diffusivity, rather than trans-endothelial transport propensity is essential for increasing 
the volume of tissue within the therapeutic window. 
 
Delivery of doxorubicin through a realistic tumor vasculature 
Tumor vasculatures have complex structures, which are abundant in chaotically 
branched microvessels that form loops and dead ends13,14,44–46. These malformed vascular 
networks typically have microvessels that vary greatly in diameter when compared to 
healthy tissues. Often there is no preferred blood flow direction or the vasculature is 
connected only to feeder arteries with no draining veins47. To explore the effect of these 
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structural features on drug delivery I modeled the vasculature of a mouse ovarian tumor 
by tracing the tumor capillaries from a positron emission tomography (PET) scan (Figure 
5A)48.  
Figure 5 shows that equilibration in the complex vasculature is rapid and the 
complexity of the vascular network branching itself presents no barrier to delivery as the 
drug distributes uniformly throughout the vessels within 180 seconds. Simulation of 
spontaneous drug diffusion out of this vasculature shows that the key barrier to delivery 
is the spacing of the blood vessels. This means that not all regions of the tumor reach 
drug concentrations that fall within the therapeutic window. While regions close to the 
vasculature are generally well saturated by doxorubicin, many regions buried deeply 
inside the tumor tissue remain effectively untreated with few or no drugs reaching this 
far. Increasing the injection dose to treat these deeply buried parts of the tumor tissue 
may result in toxic side-effects, thus rendering portions of the tumor untreatable for drugs 






Figure 5 | Application of the three-dimensional molecular mechanics model to a 
realistic vascular system. A. The tumor vasculature was modeled by tracing blood 
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vessels from an image of a mouse ovarian tumor seven days after subcutaneous 
injection. Only a subset of the tumor was modeled for simplicity and the trace was 
turned into a three-dimensional vascular structure. B. After injection into the main 
feeder artery drugs were allowed to diffuse across the vasculature. Equilibration, even 
for a complex vasculature like this one is typically completed within 30 to 60 seconds. C. 
After equilibration in the vascular network drugs start to slowly diffuse across the 
endothelium into the surrounding tissues. The figure shows the position of drug 
particles at the end of a 168-hour simulation with an initial dose of 10 million liposomes 
(equivalent to 5 ng of doxil). D. A heat-map of drug concentration in the tissue 
(300x300x300 voxel mesh) surrounding the vasculature reveals the spatial distribution 
of drugs in the various regions of the tumor. E. Analysis of larger sub-volumes within the 
tumor tissue (the target area highlighted in panels A and C), allows precise mapping of 
the therapeutic efficiency predicted. For the shown injection dose of 10 million drug 
particles (i.e. Doxil liposomes) ~35% of the target tissue reached a dose of doxorubicin 
within TW 2 (see F) and ~45% of the total target area was sufficiently saturated with 
drugs to kill tumor cells. F. The inset includes three therapeutic windows, TW 1, TW 2, 
and TW 3, which denote a wide, intermediate, and narrow therapeutic window, 
respectively. The initial dose was sequentially iterated between 0 and 10 nanograms of 
Doxil, to determine the percentages of the drugs within the therapeutic window. The 
effects of the therapeutic window, drug kinematic properties, and vascular structure are 





Drugs like doxorubicin have a permeability of at least 10-9 cm2/s and a 
transendothelial transport probability of approximately 10-6 when there a collision with 
blood vessel walls given a simulation time step of 1 second. Improving therapeutic 
efficacy (i.e. increasing the tumor volume within the therapeutic window) can be 
achieved by enhancing the transendothelial transport rate and tissue diffusivity. In 
general, the optimal dose depends on a maximal tumor volume obtaining drug 
concentrations within the therapeutic window, which is constrained by the tumor 
vasculature. Figures 5 & 6 show optimized doses for a specific target area within a tumor. 
These have been calculated using the scheme for dosage optimization in Figure 6. 
Optimal dosimetry depends on all inputs to my model (i.e. vascular and tissue fine-
structure, trans-endothelial transfer probabilities, tissue diffusivities, clearance rates, and 
therapeutic window). The initial dose was increased iteratively to discover the optimal 
dose in both target areas. The optimal dose for the targets shown in Figures 5 & 6 with a 
therapeutic window of 5-50 pharmacophores per 37 µm3 is around 2.5 and 10 ng/mm3 of 
tumor, respectively. These dosages result in 35-43% of the target volume receiving a 







Figure 6 | Optimizing the volume within different therapeutic windows for a target 
area in a tumor tissue. A. The concentrations within the voxels inside a different target 
area from Figure 5 sorted in ascending order. The initial injection was of 10,000,000 
particles for the entire system. The resulting curve shows the percentage of voxels with 
a given concentration at the end of the simulation. Three therapeutic windows were 
proposed: large (window 1: 5-50 doxorubicin per 37 µm3 voxel), medium (window 2: 20-
35 doxorubicin per voxel), and narrow (window 3: 25-30 doxorubicin per voxel). 
Rectangles representing the window are overlaid, where the height of the rectangle 
represents the width of the therapeutic window, and the width of the rectangle 
27 
 
represents the percentage volume of the tumor with concentrations within that 
window. B. Percentages of therapeutic dose in the target tissue are plotted with respect 
to the number of Doxil liposomes injected at the beginning of the simulation. The 
procedure to discover the optimal dose was iterated involved many simulations with 
initial injections of 0 to 2x107 Doxil in 5x104 increments, by calculating the horizontal 
width of the therapeutic window at the end of the simulation (t = 168 hrs). Maximum 
therapeutic intensities vary and are denoted by stars, which is demonstrative of the 
arduous fine-tuning which can be possible for drugs of various toxicities and kinematics 
to be optimally effective within a given vascularization of a tumor. 
 
Comparison of doxorubicin payloads via liposomal and direct doxorubicin 
administration 
I calculated the tumor delivery efficiency of equivalent molar quantities of 
doxorubicin via injection of two different formulations: Doxil liposomes and doxorubicin 
molecules (Figure 7). Injection of 9.6x105 Doxil liposomes (approximately 0.5 ng with 
parameters above), resulted in approximately 1% of the dose accumulating in the tumor 
over the course of 168 hours (Figure 7AD). The tissue penetration depth (i.e. average 
distance of a Doxil molecule from the surface of the nearest blood vessel) per Doxil was 
10.7±8.7 micrometers. The final locations of each Doxil that reached the tissue was then 
replaced with 50 doxorubicin molecules, each simulated as a single doxorubicin 
molecule, but statistically representing 1000 doxorubicin molecules being released from 
the Doxil liposome. The resulting dispersion of doxorubicin resulted in minimal back-
transfer into the blood stream (less than 3%), and a resulting dose of ~50 pg doxorubicin 
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to the tissue, with average tissue penetration of 46.5±29.4, micrometers (Figure 7BD). 
The amount of doxorubicin cleared in blood from both Doxil and Doxil-released 
doxorubicin clearance was 0.495 ng.  
In contrast, direct injection of 5x106 doxorubicin molecules (again each 
representing 1000 molecules) in uniform concentration throughout the vasculature 
resulted in a dose delivered to the tumor of ~18 pg, and the an average tissue penetration 
of 46.0±29.1 micrometers, with 0.498 ng of the dose being cleared by blood (Figure 
7CD). 
This demonstrates that injection of Doxil more than doubles the dose of 
doxorubicin delivered into the tumor, while tissue penetration and clearance of 
doxorubicin remain roughly identical. However, clearance of doxorubicin is on the 
timescale of minutes, while Doxil clearance is over the timescale of days resulting in a 
reduction of toxic side-effects. At present it is unclear how doxorubicin is released from 
Doxil upon accumulation in tumor tissue. However, the present simulations provide a 
quantitative estimate of the EPR effect, irrespective of the liposomal release mechanism, 





Figure 7 | Comparison of doxorubicin delivery into tumor using direct injection and 
Doxil after 168 hours. A. This panel shows the final position of doxil liposomes that 
spontaneously diffused from the vasculature into the tissue after 168 hours. The 
simulation parameters for Doxil were Dvasc = 1x10






tumor = kdelivery = k
eliminiation
 x 10
-2. B. Each of the 
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coordinates from the Doxil simulation in panel A were replaced by 50 doxorubicin 
clusters, each representing 1000 actual doxorubicin molecules, which were allowed to 
diffuse until they were cleared from the tumor. The parameters for these doxorubicin 
molecules are Dvasc = 1x10
-5 cm2/s, Dtissue = 1x10
-9 cm2/s, keliminiation = 1.57 hr
-1, k+
tumor
 =   
k-
tumor = kdelivery = k
eliminiation
 x 10
-2. C. 4,684,500 doxorubicin clusters were injected and 
equilibrated in the vasculature like in simulation A, and were allowed to diffuse into the 
tissue. 19,769 doxorubicin clusters reached the tumor compared to 54,065 in simulation 
B. D. Comparison of the mean tissue permeation (i.e. the average distance from each 
pharmacophore to the nearest vascular segment) and the percentage of initial dose for all 
three simulations. The percentage of initial dose for B is referenced to the scaled dose of 
50 times the dose A in order to capture the number of doxorubicin cleared in blood 
throughout simulation A, as 97.4% of the doxorubicin clusters which were released from 
the liposomes of A remained in the tumor tissue. The values for mean tissue permeation 
of systems A, B, and C, were 11±9 μm, 47±29 μm, and 46±29 μm, respectively. The 
population standard deviation values are denoted by the vertical black bar centered at 
each bar. The percentages of doxorubicin molecules reaching the tumor tissue of systems 
A, B, and C, were 1.24, 1.15, and 0.42, respectively. These results show quantitatively 
that doxorubicin, due to its small size penetrates much deeper into the tumor tissues than 
Doxil. However, the much lower clearance rate of Doxil, together with the negligible 
diffusion back into the vasculature, results in an accumulation of Doxil just beyond the 
tumor endothelium. This ultimately results in a much higher quantity of doxorubicin 





The key goal of the present study was to develop a computational model that 
accurately simulates the delivery of drugs through realistic three-dimensional vascular 
networks into a solid tumor. Delivery is calculated by tracking the Brownian motion of 
drug molecules that move freely through the vasculature, across the endothelium, and 
into tumor tissue. Accurate description of the motion and kinetics by this model requires 
a priori information about the diffusivities of the drugs in blood and tissues, as well as 
the transport rate across the tumor vessel endothelium. Long timescale simulations also 
require an estimate of the clearance rate via liver, kidney, macrophages, peripheral 
tissues, etc. 
Diffusion constants for drugs in a tumor have been measured in pre-clinical 
studies and range from (D = 10-5 – 10-9 cm2/s) in rabbits for the small drug doxorubicin 
HCl (MW = 580 Da)49 to (D = 10-9 – 10-13 cm2/s) for the 100 nm diameter PEGylated 
liposomal formulation Doxil37, which encapsulates ~48,000 doxorubicin molecules per 
liposome50. Molecular diffusion constants through the interstitial space of living tissues 
are more difficult to obtain and are likely to vary between different tissue types. For the 
present study, I estimated tissue diffusivity for Doxil to be 1x10-12 cm2/s, in line with 
previous studies21,33,51. To investigate the impact of drug weight, size, polarity, and 
interaction with endothelia and tissue environments, I explored the effect of varying the 
diffusivity by eight orders of magnitude (10-12 – 10-4 cm2/s) (see Figure 4). This suggests 
that payloads of low therapeutic index should have a tissue diffusivity of at least 10-8 
cm2/s to be pharmaceutically effective in penetrating deeply into tumor tissues, 
depending on the eliminative and distributive half-lives of the drug.  
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Estimating the transport barrier of drugs across a unit area of tumor vasculature is 
non-trivial. Transendothelial transport is dominated by the leaky vasculature and hence 
expected to be similar for most drugs, especially if delivered via a nanoparticle 
formulation. Varying the transendothelial probability between 10-3 – 10-5, a range 
considerably higher than Doxil’s rate-derived parameter of ~6 x 10-7 given a simulation 
time increment of 1 second, indicates that a transport probability exceeding 10-4 is 
desirable for therapeutic efficiency, particularly for slowly diffusing drugs or drug 
delivery vehicles (see Figure 4). 
Simulation of 107 Doxil liposomes diffusing through a realistic tumor vasculature, 
mapped from a mouse ovarian PET/CT scan image47, permitted calculation of the 
percentage of tumor tissues receiving drug doses that fall within the therapeutic window 
(see Figure 5 of a tumor patch). This revealed that the three-dimensional structure of the 
vasculature is important for drug delivery efficiency due to two key factors: first, the 
diameter of the blood vessel scales inversely with the rate of diffusion of drugs into 
tumor tissues; and secondly, the weighted distance of tissue areas to surrounding 
capillaries determines the final drug concentration. Both effects depend directly, 
significantly, and non-trivially on the actual three-dimensional vascular structure.  
At present the mechanistic details of how Doxil kills cells via release of its toxic 
doxorubicin warhead inside the tumor are not fully understood. A typical therapeutic 
dose of 100 mg Doxil contains roughly 1014 liposomes, each containing ~48,000 
doxorubicin molecules. Assuming a final tumor delivery range of 0.1% to 1.0% of the 
administered dose, a 1 cm3 tumor, consisting of approximately 109 cells, will take up 
1011–1012 Doxil liposomes, outnumbering the cells in the tumor by 2–3 orders of 
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magnitude. Comparison of the delivery of doxorubicin versus Doxil (see Figure 7) 
suggest a mechanism where Doxil, due to its long half-life, high permeability, and low 
tissue diffusivity, accumulates just behind the tumor endothelium. Killing of cells buried 
in the tumor is then achieved by release of doxorubicin, which has a much higher tissue 
diffusivity than Doxil and is able to penetrate deeply into the tumor without getting 
cleared by MPS, the kidneys, or the liver. While the simulation does not show how the 
doxorubicin molecules leave the liposome, it would be consistent with Doxil being taken 
up by the cell (e.g. via endocytosis), and subsequent release of doxorubicin molecules 
upon cell death.  
The results suggest that other structural features common in tumors, such as 
necrotic tissues and blood lakes may also be important for predicting how drugs are 
distributed throughout the tumor tissue. Since the present model assumes no interaction 
between drug molecules, which is reasonable for liposome-based delivery vehicles as 
well as typical dosage regimens, the final concentration scales linearly with the initial 
dosage, allowing extrapolation from computationally feasible to clinically relevant doses. 
The present model demonstrates that spatial information on the efficiency of drug 
delivery into target tissues in the body can be obtained using molecular mechanics 
techniques that track the diffusive motion of individual particles. The key advantage of 
this approach is that the input parameters are specific to a particular drug or formulation. 
Once the vascular and tissue diffusivities, transendothelial permeabilities, and 
pharmacokinetic clearance rates have been determined, the model can be applied to 
predict the delivery of a drug or drug delivery system to any target tissue for which three-
dimensional structural data can be obtained via clinical computed tomography (CT) or 
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other molecular imaging technique. This has a broad range of potential applications 
including dosage optimization for drugs with small therapeutic windows, which are 
common in cancer therapy, as well as selecting drugs that have tissue penetration 
properties that are more suited to a particular tumor. While conventional clinical CT 
scanners have a typical resolution of 240 µm, too coarse to capture the fine structure of 
10-100 µm capillaries inside a tumor, advanced clinical scanners exist which provide 
resolutions of down to 30 microns52,53. For research purposes µCT machines are available 
with sub-micrometer resolutions, allowing full visualization of even the smallest 
capillaries. Future improvements in clinical CT and MRI technology will ultimately 
allow prediction of the optimal drug dosage regimen for a particular patient and target 
tissue using structural imaging and modeling of drug delivery. At present my 
methodology can be used to screen the effectiveness and optimize the dose of any 
medication, especially where uptake into different tissues and microenvironments varies 
using non-clinical µCT tissue scans. 
Chemotherapy outcomes depend critically upon the ability of an anticancer drug 
to penetrate tumor tissues and cancerous cells at therapeutic concentrations. Systematic 
optimization of delivery necessitates the development of a more detailed understanding 
of how drugs enter tissues. The present study shows that there is scope for improvement 
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Table A1 | Key parameters used in the structural model     
Parameter  Value 




Dvasculature (Doxil) 1 x 10
-6 cm2/s 
Dvasculature (doxorubicin) 1 x 10
-5 cm2/s 
Dtissue          (Doxil) 1 x 10
-12 cm2/s 
Dtissue          (doxorubicin) 1 x 10
-9 cm2/s 
kelimination (Doxil) 0.0204 - 0.0228 (hr-1) 
kelimination  (doxorubicin) 1.56823 (hr-1) 
k+
tissue         (Doxil) (Fig 3) 0.0956 (hr-1) 
k-
tissue          (Doxil) (Fig 3) 0.198 (hr-1) 
k+
tumor         (Doxil) 0.0000228 - 0.00228 (hr-1) 
k-
tumor          (Doxil) 0 – 0.00228 (hr-1) 
k+
tumor         (doxorubicin) 0.0156823 (hr-1) 
k-
tumor          (doxorubicin) 0.0156823 (hr-1) 
kdelivery        (Doxil) 0.000228 (hr-1) 
kdelivery        (doxorubicin) 0.0156823 (hr-1) 
pelimination   (Doxil) 5.67 – 6.33 x 10-6  
pelimination   (doxorubicin) 5.67 – 6.33 x 10-6  
p+
tissue          (Doxil) (Fig 3) 2.66 x 10-5  
p-
tissue           (Doxil) (Fig 3) 5.50 x 10-5  
p+
tumor         (Doxil) 6.33 x 10-9 – 6.33 x 10-7  
p-
tumor          (Doxil) 0 – 6.33 x 10-7  
p+
tumor         (doxorubicin) 64.36 x 10-6  
p-
tumor          (doxorubicin) 4.36 x 10-6  
pdelivery        (Doxil) 6.33 x 10-8  
pdelivery        (doxorubicin) 4.36 x 10-6  
 
Ndose = Number of liposomes simulated during the majority of the study, Vsystem = 
simulated volume of tissue and vasculature. Dvasculature = diffusion coefficient of 
therapeutics in the vasculature, Dtissue = diffusion coefficient of therapeutics in the both 
tumorous and healthy tissues, kelimination = first-order rate constant for eliminating 
therapeutics from the system, k+
tissue = first-order rate constant for therapeutics to transfer 
from blood to peripheral tissues, k-
tissue = first-order rate constant for therapeutics to 
transfer from peripheral tissues to blood, k+
tumor = first-order rate constant for therapeutics 
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to transfer from blood to tumor, k-
tumor = first-order rate constant for therapeutics to 
transfer from tumor to blood, kdelivery = first-order rate constant for therapeutics to finish 
releasing their payload within the tumor, pelimination = per-particle Monte Carlo elimination 
probability within a simulation time-step of one second. p+
tissue = per-particle Monte Carlo 
probability of transfer between blood and peripheral tissue within a simulation time-step 
of one second. p-
tissue = per-particle Monte Carlo probability of transfer between 
peripheral tissue and blood within a simulation time-step of one second. p+
tumor = per-
particle Monte Carlo probability of transfer between blood and tumor tissue within a 
simulation time-step of one second. p-
tumor = per-particle Monte Carlo probability of 
transfer between tumor tissue and blood within a simulation time-step of one second 
pdelivery = Monte Carlo probability of completed delivery to tumor within a simulation 




Table A2 | Parameters for system 1 (parallel capillaries Figure 2A) 
Parameter Value 
Number of cylinders 36 
Inter-capillary spacing of vessel array 1 
(sufficient) 
50.0 μm 
Inter-capillary spacing of vessel array 2 
(insufficient) 
100.0 μm 
Maximum vessel width 37.0 μm 
Minimum vessel width 10.0 μm 
Average vessel width 17.9 μm 
Standard deviation of vessel width 7.0 μm 
Maximum vessel length 115.0 μm 
Minimum vessel length 370.7 μm 
Average vessel length 211.8 μm 
Standard deviation of vessel length 80.4 μm 
Maximum vessel surface area 5.42 x 103 μm2 
Minimum vessel surface area 3.49 x 104 μm2 
Average vessel surface area 1.12 x 104 μm2 
Standard deviation of vessel surface area 5.64 x 103 μm2 
Maximum vessel volume 2.03 x 104 μm3 
Minimum vessel volume 2.62 x 105 μm3 
Average vessel volume 5.58 x 104 μm3 
Standard deviation of vessel volume 5.08 x 104 μm3 
 
System 1 was inspired to test the simple effect on intercapillary distance on the 
simultaneous therapeutic uptake of the surrounding tissues. The widths were based on 
textbook values which agree to data obtained within existing micrographs of human 
microvasculature13,14,46. The other parameters are calculated using only the information 




Table A3 | Parameters for system 2 (simple microtumor Figure 2B) 
Parameter Value 
Number of cylinders 24 
Minimum vessel width 10.0 μm 
Maximum vessel width 37.0 μm 
Average vessel width 14.0 μm 
Standard deviation of vessel width 7.7 μm 
Minimum vessel length 50.0 μm 
Maximum vessel length 316.2 μm 
Average vessel length 133.7 μm 
Standard deviation of vessel length 59.8 μm 
Minimum vessel surface area 1.57 x 103 μm2 
Maximum vessel surface area 2.78 x 104 μm2 
Average vessel surface area 6.48 x 103 μm2 
Standard deviation of vessel surface area 6.15 x 103 μm2 
Minimum vessel volume 3.93 x 103 μm3 
Maximum vessel volume 1.95 x 105 μm3 
Average vessel volume 3.29 x 104 μm3 
Standard deviation of vessel volume 5.31 x 104 μm3 
 
System 2 was inspired to be a simple microtumor with only a few branches from a source 
arteriole and leading into a draining venule. The widths were based on textbook values 
which agree to data obtained within existing micrographs of human 
microvasculature13,14,46. The other parameters are calculated using only the information 






Table A4 | Parameters for system 3 (planar capillary Figure 2C) 
Parameter Value 
Number of cylinders 48 
Minimum vessel width 10.0 μm 
Maximum vessel width 10.0 μm 
Average vessel width 10.0 μm 
Standard deviation of vessel width 0.0 μm 
Minimum vessel length 55.9 μm 
Maximum vessel length 293.4 μm 
Average vessel length 145.3 μm 
Standard deviation of vessel length 54.5 μm 
Minimum vessel surface area 1.76 x 103 μm2 
Maximum vessel surface area 9.22 x 103 μm2 
Average vessel surface area 4.57 x 103 μm2 
Standard deviation of vessel surface area 1.71 x 103 μm2 
Minimum vessel volume 4.39 x 103 μm3 
Maximum vessel volume 2.30 x 104 μm3 
Average vessel volume 1.14 x 103 μm3 
Standard deviation of vessel volume 4.28 x 103 μm3 
 
System 3 is motivated to be a simple planar capillary mesh, in which flow directions would 
be difficult to calculate using continuum methods. The widths were chosen to be uniform 
with a value that exists within existing micrographs of human endothelia13,14,46. The other 
parameters are calculated using only the information obtained from the cylindrical 




Table A5 | Parameters for system 4 (mouse ovarian tumor Figure 5). 
Parameter Value 
Number of cylinders 201 
Minimum vessel width 5.1 μm 
Maximum vessel width 19.9 μm 
Average vessel width 12.8 μm 
Standard deviation of vessel width 4.48 μm 
Minimum vessel length 10.5 μm 
Maximum vessel length 180.4 μm 
Average vessel length 43.7 μm 
Standard deviation of vessel length 26.9 μm 
Minimum vessel surface area 2.27 x 102 μm2 
Maximum vessel surface area 5.81 x 103 μm2 
Average vessel surface area 1.74 x 103 μm2 
Standard deviation of vessel surface area 1.18 x 103 μm2 
Minimum vessel volume 3.14 x 102 μm3 
Maximum vessel volume 2.68 x 104 μm3 
Average vessel volume 6.22 x 103 μm3 
Standard deviation of vessel volume 5.40 x 103 μm3 
 
System 4 was generated by hand-tracing coordinates in a plane over the image provided 
from a PET image of an ovarian mouse tumor47. The widths were scaled 
programmatically and by eye to match the outline of the blood vessels, but better 
algorithms need to be developed in further studies of realistic vasculature. The other 
parameters are calculated using only the information obtained from the cylindrical 
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